MEKK2 mediates an alternative β-catenin pathway that promotes bone formation

Authors:

Abstract
Proper tuning of β-catenin activity in osteoblasts is required for bone homeostasis, because both increased and decreased β-catenin activity have pathologic consequences. In the classical pathway for β-catenin activation, stimulation with WNT ligands suppresses constitutive phosphorylation of β-catenin by glycogen synthase kinase 3β, preventing β-catenin ubiquitination and proteasomal degradation. Here, we have found that mitogen-activated protein kinase kinase kinase 2 (MAP3K2 or MEKK2) mediates an alternative pathway for β-catenin activation in osteoblasts that is distinct from the canonical WNT pathway. FGF2 activates MEKK2 to phosphorylate β-catenin at serine 675, promoting recruitment of the deubiquitinating enzyme, ubiquitin-specific peptidase 15 (USP15). USP15 in turn prevents the basal turnover of β-catenin by inhibiting its ubiquitin-dependent proteasomal degradation, thereby enhancing WNT signaling. Analysis of MEKK2-deficient mice and genetic interaction studies between Mekk2- and β-catenin–null alleles confirm that this pathway is an important physiologic regulator of bone mass in vivo. Thus, an FGF2/MEKK2 pathway mediates an alternative nonclassical pathway for β-catenin activation, and this pathway is a key regulator of bone formation by osteoblasts. Significance Here, we report a previously unidentified alternative pathway mediated by mitogen-activated protein kinase kinase kinase 2 (MEKK2) for the activation of β-catenin in osteoblasts that is distinct from the classical glycogen synthase kinase 3β (GSK3β)-mediated degradation pathway. The GSK3β pathway regulates β-catenin stability via β-catenin ubiquitination, and its inhibition prevents β-catenin degradation. The MEKK2 pathway instead rescues ubiquitinated β-catenin from degradation via deubiquitination. This pathway plays a critical role in controlling bone mass in vivo, and targeting this pathway may offer an attractive approach for the therapeutic regulation of β-catenin activity.
Funding Information
  • Burroughs Wellcome Fund (1014758)
  • HHS | NIH | NIH Office of the Director (1DP5OD021351)

This publication has 40 references indexed in Scilit: